STAT+: FDA approves novel Bayer drug to reduce recurrence of stroke
The Food and Drug Administration on Monday approved Bayer’s drug to reduce recurrence of stroke, making available the first in a novel class of medications that hold the promise of preventing blood clots more safely.
Key points
- Another way to look at the data is that in one year, 53 patients need to be treated for one recurrent stroke to be prevented.
- Continue to STAT+ to read the full story….
- Many blood thinners aren’t used in this setting due to the increased risk of bleeding.
But Bayer’s drug, which will be sold under the brand name Sunharbo, inhibits a protein called XIa, utilizing a mechanism that’s thought to stop the formation of bad clots without increasing the risk of bleeding.
How this summary was made: extractive summary — built from the sources' own reporting. It is drawn only from the reporting of the sources listed below — read the originals for full detail. How we summarize →
Advertisement
Every article behind this summary — 1 article from 1 outlet
Get stories like this in your inbox.
Subscribe — it's freeOne free email at 6am — your topics, deduplicated, five minutes. No account, no paywall.